Erenumab

Generic Name: Erenumab

Brand Names: Aimovig

Drug Type: Biotech

CAS Number: 1582205-90-0

Unique Ingredient Identifier: I5I8VB78VT

Background: Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine .

In particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity binding to the CGRP receptor . The antibody is produced utlilizing recombinant DNA technology in Chinese hamster ovary cells . It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa .

Indication: Erenumab is indicated for the preventative treatment of migraine in adults .

Associated Conditions: Migraine

Clinical Trials

Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain

Phase 3

Terminated

Conditions: Fibromyalgia

Interventions: Drug: Saline
Drug: Erenumab

First Posted Date: 2024-05-13

Last Posted Date: 2024-05-13

Lead Sponsor: United States Naval Medical Center, Portsmouth

Target Recruit Count: 5

Registration Number: NCT06411067

Locations: 🇺🇸
Naval Medical Center Portsmouth, Portsmouth, Virginia, United States

Migraine Medication Effects on Urinary Symptoms

Conditions: Bladder Pain Syndrome
Migraine Disorders
Migraine
Overactive Bladder
Overactive Bladder Syndrome
Overactive Detrusor
Interstitial Cystitis

Interventions: Drug: Ubrogepant
Drug: Botulinum toxin A
Drug: Rimegepant
Drug: Atogepant
Drug: Eptinezumab
Drug: Fremanezumab
Drug: Galcanezumab
Drug: Erenumab

First Posted Date: 2024-01-19

Last Posted Date: 2024-05-16

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 200

Registration Number: NCT06212661

Locations: 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States

Aimovig Pregnancy Exposure Registry

Recruiting

Conditions: Migraine

Interventions: Drug: erenumab-aooe

First Posted Date: 2023-11-29

Last Posted Date: 2024-10-03

Lead Sponsor: Amgen

Target Recruit Count: 2842

Registration Number: NCT06150781

Locations: 🇺🇸
IQVIA Virtual Site, Durham, North Carolina, United States

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Phase 2

Recruiting

Conditions: Schwannomatosis
Schwannomas
Pain, Chronic

Interventions: Drug: Siltuximab
Drug: Erenumab-Aooe
Drug: Siltuximab Matching Placebo
Drug: Erenumab-Aooe Matching Placebo

First Posted Date: 2023-01-13

Last Posted Date: 2024-03-13

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT05684692

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment

Completed

Conditions: Migraine

First Posted Date: 2022-07-01

Last Posted Date: 2022-07-01

Lead Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation

Target Recruit Count: 53

Registration Number: NCT05442008

Locations: 🇮🇹
Headache Science & Neurorehabilitation Center, Pavia, Italy

Real World Effectiveness of Eptinezumab in Participants With Migraine

Phase 4

Terminated

Conditions: Migraine

Interventions: Drug: Eptinezumab
Drug: Onabotulinumtoxin-A
Drug: Erenumab
Drug: Fremanezumab
Drug: Galcanezumab

First Posted Date: 2022-03-17

Last Posted Date: 2024-05-29

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 32

Registration Number: NCT05284019

Locations: 🇺🇸
Gilbert Neurology Partners/ CCT Research, Gilbert, Arizona, United States
🇺🇸
Ki Clinical Research LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸
Innovation Medical Group, Palmetto Bay, Florida, United States

and more 7 locations

Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

Recruiting

Conditions: Migraine
Migraine With Aura
Migraine Without Aura
Chronic Migraine
Episodic Migraine

Interventions: Drug: Erenumab
Drug: Galcanezumab
Drug: Fremanezumab

First Posted Date: 2022-03-16

Last Posted Date: 2022-10-20

Lead Sponsor: Austrian Migraine Registry Collaboration

Target Recruit Count: 1500

Registration Number: NCT05281770

Locations: 🇦🇹
Medical University Innsbruck, Innsbruck, Tirol, Austria
🇦🇹
Clinic Hietzing, Vienna, Austria
🇦🇹
Medizinische Universität Wien, Wien, Vienna, Austria